Rezolute, Inc. (RZLT) Research

Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema. Founded in 2010, the entity was formerly known as AntriaBio, Inc. before adopting the Rezolute, Inc. name in December 2017, and its operations are based out of Redwood City, California.

Market snapshot

Symbol
RZLT
Price
$5.02
Day change
+4.80%
Market cap
$483.4M
P/E ratio
-6.41x
52-week range
1.07-11.457
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months
Analyst price target
$8.67

Recent news

  • Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

    Rezolute, Inc. (NASDAQ:RZLT) reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI), saying six of the eight participants enrolled so far achieved the study's primary endpoint.

  • FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question

    In a recent update, Rezolute shared insights from its March 17 meeting with the FDA regarding its Phase 3 sunRIZE trial for ersodetug, aimed at treating congenital hyperinsulinism.

Peer companies

  • Day One Biopharmaceuticals, Inc. (DAWN)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Geron Corporation (GERN)
  • Kura Oncology, Inc. (KURA)
  • Maravai LifeSciences Holdings, Inc. (MRVI)
  • Nanobiotix S.A. (NBTX)
  • Prime Medicine, Inc. (PRME)
  • ProKidney Corp. (PROK)

Recent insider activity

  • Evans Daron — P-Purchase (10000 shares) on 2026-03-30
  • ROBERTS BRIAN KENNETH — F-InKind (11439 shares) on 2026-03-02
  • Evans Daron — F-InKind (11438 shares) on 2026-03-02
  • Elam Nevan C — F-InKind (27618 shares) on 2026-03-02
  • Hogenhuis Wladimir — P-Purchase (5650 shares) on 2025-12-16

Open Rezolute, Inc. (RZLT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.